The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
Open accessAbstract
BACKGROUND: We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials. METHODS: Patients ⩾18 years received oral sunitinib 50 mg per day on a 4-weeks-on-2-weeks-off schedule. Safety was assessed regularly. Tumour measurements were scheduled per local practice. RESULTS: A total of 4543 patients received sunitinib. Median treatment duration and follow-up were 7.5 and 13.6 months. Objective response rate was 16% (95% confidence interval (CI): 15-17). Median progression-free survival (PFS) and overall survival (OS) were 9.4 months (95% CI: 8.8-10.0) and 18.7 months (95% CI: 17.5-19.5). Median PFS in subgroups of interest: aged ⩾65 years (33%), 10.1 months; Eastern Cooperative Oncology Group performance status ⩾2 (14%), 3.5 months; non-clear cell histology (12%), 6.0 months; and brain metastases (7%), 5.3 months. OS was strongly associated with the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (n=4065). The most common grade 3/4 treatment-related adverse events were thrombocytopenia (10%), fatigue (9%), and asthenia, neutropenia, and hand-foot syndrome (each 7%). CONCLUSION: Final analysis of the sunitinib expanded-access trial provided a good opportunity to evaluate the long-term side effects of a tyrosine kinase inhibitor used worldwide in mRCC. Efficacy and safety findings were consistent with previous results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Self-citationKidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 571
Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00720-2 · Cited by 86
Patients' perspective on digital technologies in advanced genitourinary cancers
Rodler, S., Buchner, A., Stief, C. G., Heinemann, V., Staehler, M., & Casuscelli, J. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.03.018 · Cited by 27
Metadata
- Authors
- Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Lee, S.-H., Haanen, J., Castellano, D., Vrdoljak, E., Schöffski, P., Mainwaring, P., Hawkins, R. E., Crinò, L., Kim, T. M., Carteni, G., Eberhardt, W. E. E., Zhang, K., Fly, K., Matczak, E., Lechuga, M. J., Hariharan, S., & Bukowski, R.
- Venue
- British Journal of Cancer
- Published
- 2015-06
- Volume
- 113
- Issue
- 1
- Pages
- 12-19
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1564728191
- Cited by
- 187
- References
- 1
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. https://app.cochat.ai/papers/10.1038/bjc.2015.196
- The paper
- Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Lee, S.-H., Haanen, J., Castellano, D., Vrdoljak, E., Schöffski, P., Mainwaring, P., Hawkins, R. E., Crinò, L., Kim, T. M., Carteni, G., Eberhardt, W. E. E., Zhang, K., Fly, K., . . . Bukowski, R. (2015). Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. British Journal of Cancer. https://doi.org/10.1038/bjc.2015.196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.